GLP-1 Drugs Changed Peptide Manufacturing Forever: Here Is What the Industry Is Doing to Keep Up In June 2021, the FDA approved Wegovy, the semaglutide-based obesity treatment from Novo Nordisk, and the global pharmaceutical industry entered a chapter it was entirely unprepared for
While early GLP1 drugs focused primarily on diabetes, newer agents, such as tirzepatidebased therapies, have gained traction in treating obesity, raising efficacy expectations and increasing competitive dynamics
Does Blue Cross Blue Shield MA cover GLP-1 medications
Farooqi IS, Wangensteen T, Collins S, et al
Clinical Evaluation: You will connect with an expert clinician online who will quickly evaluate your survey results